FindTrial
Sign In

Efficacy and Safety of Interferon-Gamma Combined with Camrelizumab in Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Efficacy and Safety of Interferon-Gamma Combined with Camrelizumab in Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121346
Enrollment
Unknown
Registered
2026-03-30
Start date
2026-03-31
Completion date
Unknown
Last updated
2026-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

Research group:interferon-? combined with camrelizumab and neoadjuvant chemotherapy

Sponsors

Hefei Cancer Hospital, Chinese Academy of Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Aged >= 18 years; 2. Histologically confirmed esophageal squamous cell carcinoma (ESCC), clinical stage cT1b-3, N+, M0; 3. Eastern Cooperative Oncology Group (ECOG) performance status 0–1; 4. Expected overall survival > 6 months; 5. Adequate bone marrow, hepatic, renal, coagulation, and thyroid function.

Exclusion criteria

Exclusion criteria: 1. Active autoimmune disease; 2. Requirement for systemic immunosuppressive therapy; 3. Hypersensitivity to any study drug; 4. Uncontrolled significant organ disease (e.g., cardiac, pulmonary, hepatic, renal) or active infection; 5. Pregnant or lactating female.

Design outcomes

Primary

MeasureTime frame
Pathological complete response rate;—

Secondary

MeasureTime frame
Objective Response Rate;Progression-free survival;Overall Survival;Duration of relief;—

Countries

China

Contacts

Public ContactHongzhi Wang

Hefei Cancer Hospital, Chinese Academy of Sciences

wanghz@hfcas.ac.cn+86 551 6589 5180

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 17, 2026